Abstract
Treatment of soft tiusse sarcoma (STS) with the combination of trabectedin and the anti-PD1 antibody nivolumab suggests to be a promising treatment approach as the combination produces a synergistic antitumor effect in a murine model of ovarian cancer. Moreover, the antitumor activity of trabectedin is partially mediated by macrophage depletion and different immunologic effects. Thus, it seems reasonable to evaluate the efficacy and safety of trabectedin plus nivolumab as a second-line option in anthracycline-pretreated sarcomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
